• Celldex outlined late-stage plans for barzolvolimab (CDX-0159), a KIT-antagonist antibody targeting mast cell-driven inflammatory diseases.
• Phase 3 CSU program enrollment finished 6 months ahead of guidance; topline data expected Q4 2026; BLA filing planned for 2027.
• Two Phase 3 CSU trials plan 1,939 patients across 43 countries; primary endpoint is mean change in UAS7 at Week 12.
• Phase 3 ColdU and symptomatic dermographism study initiated December 2025 under a global chronic inducible urticaria program.
• Phase 2 barzolvolimab studies in prurigo nodularis and atopic dermatitis are fully enrolled; topline data expected summer 2026 and late 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.